Your browser doesn't support javascript.
loading
Tocilizumab in patients hospitalized with COVID-19 pneumonia: systematic review and meta-analysis of randomized controlled trials.
Gupta, Samiksha; Padappayil, Rana Prathap; Bansal, Agam; Daouk, Salim; Brown, Brent.
Afiliación
  • Gupta S; Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
  • Padappayil RP; Department of Internal Medicine, Monmouth Medical Center, Long Branch, New Jersey, USA.
  • Bansal A; Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
  • Daouk S; Department of Pulmonary Medicine and Critical Care, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
  • Brown B; Department of Pulmonary Medicine and Critical Care, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA Brent-Brown@ouhsc.edu.
J Investig Med ; 70(1): 55-60, 2022 01.
Article en En | MEDLINE | ID: mdl-34561232
Tocilizumab is an interleukin receptor inhibitor that has been used in patients with COVID-19 pneumonia. There are recent randomized controlled trials (RCTs) that evaluated the efficacy and safety of tocilizumab in hospitalized patients with COVID-19 pneumonia. We performed a systematic review and meta-analysis of RCTs that evaluated the effectiveness of tocilizumab in hospitalized patients with COVID-19 not requiring mechanical ventilation. RCTs comparing tocilizumab with the standard of care treatment in hospitalized patients with COVID-19 pneumonia not requiring mechanical ventilation at the time of administration were included for analysis. The primary outcome was a composite of mechanical ventilation or 28-day mortality and the secondary outcomes were 28-day mortality and major adverse events. A total of 6 RCTs were included for the analysis. Tocilizumab was associated with a statistically significant reduction in the primary composite outcome of mechanical ventilation or 28-day mortality (risk ratio (RR): 0.83 (95% CI: 0.74 to 0.92, I2=0, tau2=0). Treatment with tocilizumab did not show a statistically significant reduction in 28-day mortality (RR: 0.90 (95% CI: 0.76 to 1.07), I2=0, tau2=0) and rate of serious adverse events (RR: 0.82 (95% CI: 0.62 to 1.10), I2=0, tau2=0). Tocilizumab was associated with a decrease in the incidence of primary outcome, that is, mechanical ventilation or death at 28 days in hospitalized patients with COVID-19 pneumonia.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Clinical_trials / Diagnostic_studies / Systematic_reviews Límite: Female / Humans / Male Idioma: En Revista: J Investig Med Asunto de la revista: MEDICINA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Clinical_trials / Diagnostic_studies / Systematic_reviews Límite: Female / Humans / Male Idioma: En Revista: J Investig Med Asunto de la revista: MEDICINA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido